San Diego, CA -- (SBWIRE) -- 01/26/2016 -- An investigation for shareholders of Chimerix Inc (NASDAQ:CMRX) over potential securities laws violations by Chimerix in connection certain financial statements was announced.

Investors who purchased shares of Chimerix Inc (NASDAQ:CMRX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Chimerix Inc (NASDAQ:CMRX) concerning whether a series of statements by Chimerix Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Chimerix, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. Shares of Chimerix Inc (NASDAQ:CMRX) grew from $15.40 per share in May 2014 to as high as $53.74 per share in July 2015.

On December 28, 2015, Chimerix Inc (NASDAQ:CMRX) announced that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection through Week 24 after transplant. Shares of Chimerix Inc (NASDAQ:CMRX) declined from $35.82 per share on December 24, 2015, to as low as $6.51 per share on December 28, 2015.

On January 22, 2016, NASDAQ:CMRX shares closed at $8.97 per share.

Those who purchased shares of Chimerix Inc (NASDAQ:CMRX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com